Travere TherapeuticsTVTX
Recorded

Travere Therapeutics 3rd Annual Guggenheim Healthcare Innovation Conference

Review the key takeaways and the transcript of this earnings call.

PeriodFY 0Duration24 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Eric DubePresident and CEO

is the continued strong performance of FILSPARI. We were able to reach nearly 2,000 new patients during the third quarter, and as we've seen in prior years, the summer months is often slower in nephrology, with fewer patients going to visit. That's exactly what we saw in the third quarter of last year, similar to the two prior years. But underlying that is a very strong continued demand for both IgA nephropathy, which is particularly important given the increased dynamism and the really exciting shift in the treatment algorithm for that condition, as well as now the continued strong uptake second quarter of our launch for FSGS. This is the only medicine approved for FSGS, and we're really just getting started with reaching many of those patients.

Eric DubePresident and CEO

We reported $200 million in net revenue for FILSPARI in the third quarter, reflecting the very strong conversion of those patient start forms to paid prescriptions, again, reflecting the strong payer access that we have, not just in IgAN that we've been able to maintain, but also very quickly for FSGS. We also shared that our progress with pegtibatinase, our enzyme replacement therapy for classical HCU, is continuing to progress very well. Our HARMONY phase III study is continuing to enroll according to our timelines, and we're on track for data in the second half of next year. Our newest program, civorebrutinib, which is a BTK inhibitor that we in-licensed this year from Everest Medicines, we are on track to file IND and some of the enabling work for us to move quickly into later-stage development.

Eric DubePresident and CEO

All in all, another very strong quarter of execution and puts us on track for where we hope to end the year in a very strong footing.

Vamil DivanAnalyst

Okay, great. Thanks for that summary, and then let's dive a little deeper on the commercial side, then I'll turn to Arseniy to go a little deeper on the pipeline, which I think does seem like 2027 will be the year of pegtibatinase and the focus on the pipeline. On FSGS, you mentioned, you guys talked about on the call too, the start forms there continue to grow in this third quarter, the first full quarter for that indication. Can you just talk about what's driving the launch, where you're seeing the uptake, and then where do you see maybe more room for growth in these coming quarters?

Eric DubePresident and CEO

Yeah, I think the key theme for the uptake that we've seen thus far in FSGS is the breadth of uptake, and that's both the breadth across the different types of FSGS. FSGS is quite different from IgA nephropathy, where there are different etiologies of FSGS, different types of patients across primary FSGS, genetic FSGS, and secondary. We are seeing broad use across those, and I think that's very encouraging because those patients all have very similar unmet need for better treatment. The other aspect of breadth is that we are seeing the broad use across nephrologists. I know that there were a lot of questions when we initially launched of whether this is going to be a bolus, whether it's going to be concentrated in certain physician practices, and that's just not the case.

Eric DubePresident and CEO

We continue to see very broad prescriptions, which in a launch, you really want to be able to see, because once a nephrologist gets a good experience, they're more likely to extend the use into their practice and that depth of prescribing. So, what I'd say is that the uptake has been very encouraging for continued performance with FSGS, given those two factors of breadth.

Vamil DivanAnalyst

Great. What do you think about the sort of competitive landscape here? Obviously, SGLT2s, there's other therapies these patients may be on, but specifically in FSGS, what are you seeing either in the near term or over the next few years as sort of the competitive landscape?

Eric DubePresident and CEO

Yeah, there really isn't anything in the near future, unfortunately, for these patients. So, there will be a continued focus on us reaching these patients as urgently as we can. There are other therapies with different mechanisms, all complementary in the mechanism of FILSPARI, and so we actually do not see anything as a direct competitor. Many of the therapies that are in development may address certain segments of FSGS, whether it's a certain genetic subtype or immune-mediated, which is primary FSGS, but nothing really that we see yet evidence of breadth. There may be another therapy that could be broad, but again, very longer term in the future and also complementary to the role of FILSPARI. So from our perspective, that foundational positioning that we have in IgA nephropathy is what we expect well into the future for FSGS.

Vamil DivanAnalyst

Okay. Great. Let's switch over to the IgAN side. How are you seeing the start forms trending so far? Maybe the fourth quarter will be a good start to build off of what you reported last week.

Vamil DivanAnalyst

Then the summer seasonality that you talked about, and you talked about even ahead of the quarter, how did that sort of compare this year to maybe what you've seen in prior years in the IgAN space?

Eric DubePresident and CEO

Well, we shared a little bit of commentary on our call last week. One, in terms of what we saw in Q3, was largely consistent with our experience in the summer months in terms of the magnitude of fewer patient visits, et cetera. But I think certainly there is the perspective that the IgAN market is growing in dynamism. What I mean by dynamism is really physicians making an active choice to treat patients differently. Rather than continue them on ACE inhibitors, SGLT2s, or steroids, they're making an active choice to prescribe an approved therapy. We're seeing that really accelerate, and we're a very solid part of that new treatment algorithm.

Eric DubePresident and CEO

Everything that we see is very much aligned with our expectations, and as I mentioned last week in terms of the start of Q4, we see continued strength in the prescribing, and everything that we see is very much aligned with our expectations.

Vamil DivanAnalyst

Okay, great. You mentioned obviously a lot of new players coming into the space here. That was certainly a big theme of the ASN meeting last month. What are you seeing in terms of the unmet need now in IgAN, especially patients who may be either on FILSPARI and starting B-cell therapies or vice versa? How are you seeing this market sort of play out? Where's the need going forward?

Eric DubePresident and CEO

Yeah, I think the need is very clearly laid out in the updated KDIGO guidelines, which anticipated this new set of treatment options, both in the kidney-targeted, like FILSPARI, as well as in the immune-targeted, like the B-cell therapies. The need is these patients need to have complete remission of their proteinuria, and the reason why that's important is any level of proteinuria is directly damaging to the kidney. Not only is it sort of the historical perspective of it's a marker of damage in the kidney, but any type of proteinuria above complete remission of 0.3 actually continues to damage healthy nephrons and also can be cardiotoxic. So, it's really important that these patients have complete remission of their proteinuria, and that's now possible with these treatment options. For many patients, it's going to require combination.

Eric DubePresident and CEO

The second aspect is stabilizing their eGFR, and that really has been a more challenging goal for the therapies that are available. That now seems to be possible, and we presented data at ASN that if you are able to get these patients earlier and in treatment-naive setting, they can actually achieve both of those with FILSPARI. So, as we look forward, the guidelines clearly lay out that patients should be on combination, and that's exactly what we expect. We're starting to see the early signs of that.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day